110 related articles for article (PubMed ID: 8012059)
1. Efficacy of camptothecin congeners in the treatment of human breast carcinoma xenografts.
Pantazis P; Kozielski AJ; Vardeman DM; Petry ER; Giovanella BC
Oncol Res; 1993; 5(8):273-81. PubMed ID: 8012059
[TBL] [Abstract][Full Text] [Related]
2. Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocamptothecin: differential response of nontumorigenic and tumorigenic human breast cells in vitro.
Pantazis P; Early JA; Kozielski AJ; Mendoza JT; Hinz HR; Giovanella BC
Cancer Res; 1993 Apr; 53(7):1577-82. PubMed ID: 8453626
[TBL] [Abstract][Full Text] [Related]
3. Establishment of human prostate tumor xenografts in nude mice and response to 9-nitrocamptothecin in vivo and in vitro does not correlate with the expression of various apoptosis-regulating proteins.
Pantazis P; Chatterjee D; Wyche J; DeJesus A; Early J; Plaschke S; Giovanella B
J Exp Ther Oncol; 1996 Sep; 1(5):322-33. PubMed ID: 9414421
[TBL] [Abstract][Full Text] [Related]
4. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin.
Giovanella BC; Hinz HR; Kozielski AJ; Stehlin JS; Silber R; Potmesil M
Cancer Res; 1991 Jun; 51(11):3052-5. PubMed ID: 2032244
[TBL] [Abstract][Full Text] [Related]
5. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models.
Schluep T; Hwang J; Cheng J; Heidel JD; Bartlett DW; Hollister B; Davis ME
Clin Cancer Res; 2006 Mar; 12(5):1606-14. PubMed ID: 16533788
[TBL] [Abstract][Full Text] [Related]
6. Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts.
Colbern GT; Dykes DJ; Engbers C; Musterer R; Hiller A; Pegg E; Saville R; Weng S; Luzzio M; Uster P; Amantea M; Working PK
Clin Cancer Res; 1998 Dec; 4(12):3077-82. PubMed ID: 9865923
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(S)-camptothecin (Rubitecan).
Giovanella BC; Stehlin JS; Hinz HR; Kozielski AJ; Harris NJ; Vardeman DM
Int J Oncol; 2002 Jan; 20(1):81-8. PubMed ID: 11743646
[TBL] [Abstract][Full Text] [Related]
8. Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins.
Pantazis P; Hinz HR; Mendoza JT; Kozielski AJ; Williams LJ; Stehlin JS; Giovanella BC
Cancer Res; 1992 Jul; 52(14):3980-7. PubMed ID: 1617674
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationship of alkyl 9-nitrocamptothecin esters.
Cao ZS; Pantazis P; Mendoza J; Early J; Kozielski A; Harris N; Giovanella B
Acta Pharmacol Sin; 2003 Feb; 24(2):109-19. PubMed ID: 12546717
[TBL] [Abstract][Full Text] [Related]
10. The activity of camptothecin analogues is enhanced in histocultures of human tumors and human tumor xenografts by modulation of extracellular pH.
Flowers JL; Hoffman RM; Driscoll TA; Wall ME; Wani MC; Manikumar G; Friedman HS; Dewhirst M; Colvin OM; Adams DJ
Cancer Chemother Pharmacol; 2003 Sep; 52(3):253-61. PubMed ID: 12783198
[TBL] [Abstract][Full Text] [Related]
11. Alkyl esters of camptothecin and 9-nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity.
Cao Z; Harris N; Kozielski A; Vardeman D; Stehlin JS; Giovanella B
J Med Chem; 1998 Jan; 41(1):31-7. PubMed ID: 9438019
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic efficacy of camptothecin derivatives against human malignant melanoma xenografts.
Pantazis P; Kozielski A; Rodriguez R; Petry E; Wani M; Wall M; Giovanella B
Melanoma Res; 1994 Feb; 4(1):5-10. PubMed ID: 8032218
[TBL] [Abstract][Full Text] [Related]
13. Relationship between plasma exposure of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite and antitumor response in mice bearing human colon carcinoma xenografts.
Zamboni WC; Jung LL; Egorin MJ; Hamburger DR; Joseph E; Jin R; Strychor S; Ramanathan RK; Eiseman JL
Clin Cancer Res; 2005 Jul; 11(13):4867-74. PubMed ID: 16000585
[TBL] [Abstract][Full Text] [Related]
14. CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo.
Hjarnaa PJ; Jonsson E; Latini S; Dhar S; Larsson R; Bramm E; Skov T; Binderup L
Cancer Res; 1999 Nov; 59(22):5751-7. PubMed ID: 10582695
[TBL] [Abstract][Full Text] [Related]
15. Preclinical studies of water-insoluble camptothecin congeners: cytotoxicity, development of resistance, and combination treatments.
Pantazis P
Clin Cancer Res; 1995 Nov; 1(11):1235-44. PubMed ID: 9815917
[TBL] [Abstract][Full Text] [Related]
16. Crystalline camptothecin-20(S)-O-propionate hydrate: a novel anticancer agent with strong activity against 19 human tumor xenografts.
Cao Z; Kozielski A; Liu X; Wang Y; Vardeman D; Giovanella B
Cancer Res; 2009 Jun; 69(11):4742-9. PubMed ID: 19458069
[TBL] [Abstract][Full Text] [Related]
17. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
Pratesi G; De Cesare M; Carenini N; Perego P; Righetti SC; Cucco C; Merlini L; Pisano C; Penco S; Carminati P; Vesci L; Zunino F
Clin Cancer Res; 2002 Dec; 8(12):3904-9. PubMed ID: 12473606
[TBL] [Abstract][Full Text] [Related]
18. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic effects of the novel camptothecin ST1481 (gimatecan) in human tumor xenografts.
Petrangolini G; Pratesi G; De Cesare M; Supino R; Pisano C; Marcellini M; Giordano V; Laccabue D; Lanzi C; Zunino F
Mol Cancer Res; 2003 Oct; 1(12):863-70. PubMed ID: 14573787
[TBL] [Abstract][Full Text] [Related]
20. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
